Please ensure Javascript is enabled for purposes of website accessibility

This 1 Big Element May Push Moderna Ahead of Pfizer

By Adria Cimino - Updated Jun 23, 2021 at 8:34AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It makes vaccine distribution much easier.

Moderna (MRNA -0.37%) and Pfizer (PFE 3.77%) have been leaders in the coronavirus vaccine space since the U.S. Food and Drug Administration authorized their vaccines in December. But these mRNA vaccines aren't identical. In this Motley Fool Live video recorded on May 28, healthcare and cannabis bureau editor and analyst Olivia Zitkus and contributor Adria Cimino discuss a difference between the Moderna and Pfizer vaccines -- and this difference may mean greater market share for Moderna.

Olivia Zitkus: My last Pfizer-related question is going to loop Moderna back in again. Like you mentioned before, they're really closely matched in terms of the number of vaccines that have been distributed in the U.S. Is there anything else that you think really sets the success of either the vaccine from Moderna and Pfizer apart, in terms of actually getting into people's arms? That's the struggle now. We have enough; it's just getting them into people's arms.

Adria Cimino: Moderna definitely has a logistics advantage. It has the temperature advantage. Moderna's vaccine can stay in refrigerator temperatures -- just standard fridge -- for up to three months. Pfizer only for one month. This is actually even better than before because Pfizer before it was five days, now it's one month. But still, it's well behind Moderna. This could represent something that is a weakness because there are certain countries and even in the U.S. there are certain areas where people just don't have the facilities to store all these vaccines, and so it's much easier to get the Moderna vaccine. Pfizer is working on improvements. They're working on a new formulation, so we will see what happens in the coming months with all of that. But for now, I'd say that Moderna has the advantage here.

Adria Cimino has no position in any of the stocks mentioned. Olivia Zitkus owns shares of Moderna Inc. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$171.18 (-0.37%) $0.63
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.11 (3.77%) $1.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/12/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.